FDA approves secukinumab for polymyalgia rheumatica; meta-analysis compares AI-assisted bedside ultrasound; ribupatide cuts weight up to 17.7%

A weekly pill organizer with seven compartments in a row and plain lids, three lids flipped open to show pills.

The Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for polymyalgia rheumatica that responds poorly to corticosteroids, the first anti-IL-17 biologic for the disease, Novartis said Nov. 16.

A meta-analysis found no significant accuracy difference between AI-assisted and visual point-of-care ultrasound for reduced heart pumping function, a phase 3 trial in China found ribupatide cut weight up to 17.7%, and the Centers for Medicare & Medicaid Services proposed Medicare Advantage prior authorization rules.

  • FDA Nov 16, 2026
    The Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for adults with polymyalgia rheumatica when corticosteroids have not worked well or a taper cannot be tolerated, Novartis said Nov. 16. In the phase 3 REPLENISH trial, published in the New England Journal of Medicine, 40.5% of patients given 150 mg plus a 24-week steroid taper reached sustained remission at week 52, versus 20.5% with placebo. Serious adverse events occurred in 15.9% versus 14.2%, and one fatal case of cryptococcal meningitis occurred with the drug, the company said.
  • AI Nov 17, 2026
    A Journal of General Internal Medicine meta-analysis published Nov. 17 pooled 28 studies with 4,647 participants on point-of-care ultrasound for reduced left ventricular systolic function. Five studies of AI-assisted ultrasound yielded a diagnostic odds ratio of 47.35 (95% CI 16.87 to 132.93), nine of visual qualitative assessment 40.53 (95% CI 15.07 to 109.00) and seven of E-point septal separation 21.77 (95% CI 10.25 to 46.28). The authors said all three methods showed moderate-to-high accuracy, with no significant differences among them.
  • Research Nov 15, 2026
    In the phase 3 GEMINI-1 trial, published in JAMA Nov. 15, 567 adults with overweight or obesity without diabetes at 55 sites in China were randomized to once-weekly subcutaneous ribupatide or placebo. At 48 weeks, the primary end point, least-squares mean body weight fell 10.7%, 16.4% and 17.7% with 2, 4 and 6 mg, versus 1.4% with placebo. Gastrointestinal adverse events were the most frequent, occurring in 47.9%, 58.2% and 63.1% of participants given the drug.
    Source: JAMA
  • Payment Nov 20, 2026
    The Centers for Medicare & Medicaid Services (CMS) proposed on Nov. 20 that Medicare Advantage plan contracts require in-network providers to submit prior authorization requests and documentation through the plan's FHIR-based prior authorization interface. Plans would have to keep covering services from terminated providers at in-network rates for at least 90 days after a termination. Supplemental food benefits would have to meet a CMS standard or be recommended by a clinician, according to CMS.
    Source: CMS
  • Policy Nov 16, 2026
    The Department of Health and Human Services (HHS) Office for Civil Rights issued a final rule Nov. 16 modifying the HIPAA Privacy Rule. It cuts the time to respond to patient requests for record copies from 30 calendar days to 15, Healthcare Dive reported, and establishes a right to receive electronic records through a personal health app, amends access fees and reduces identity verification burdens, according to HHS. It also permits disclosures to social services agencies and community-based organizations. The rule takes effect 60 days after publication, with compliance due 180 days after that, Healio reported.
  • Public health Nov 17, 2026
    The U.S. has lost the measles elimination status it earned 26 years ago, officials announced Nov. 17, after the Pan American Health Organization (PAHO) found the virus had circulated uninterrupted for more than a year, Healio reported; news reports of the decision appeared Nov. 14. Countries that lose the status must submit a plan to PAHO for getting measles back under control. In a joint statement, Centers for Disease Control and Prevention (CDC) Director Dr. Erica Schwartz said, "The measles elimination designation is not what protects Americans. Vaccination does."
  • Public health Nov 20, 2026
    The Centers for Disease Control and Prevention (CDC) said in its Nov. 20 FluView report that seasonal flu activity continues to increase nationally. In the week ending Nov. 14, 11.8% of clinical laboratory specimens tested positive for influenza, and 352 of 365 subtyped influenza A viruses (96.4%) were A(H1N1)pdm09. Visits for influenza-like illness reached 3.8%, and seven pediatric flu deaths have been reported this season. CDC recommends annual vaccination from age 6 months and says antivirals should be started as early as possible.
    Source: CDC

The weekly innovation roundup for internal medicine, published every Sunday for the week before; every item links to its sources. Latest internal medicine news · All specialties

Latest news

Tagged internal medicine, from the daily briefing

  1. GPT-5 missed none of the urgent primary care messages when six AI models screened patient portals in a Mass General Brigham test
  2. Medicare awards $47 million to 15 groups to test lifestyle and nutrition care for heart failure, dementia, diabetes, obesity and hypertension
  3. High-dose flu vaccine did not ease symptoms in adults 65 and older who still caught influenza, a substudy of a 10,140-person Danish trial finds

See all the latest news